NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $5.62 +0.13 (+2.37%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.44▼$5.7650-Day Range$5.28▼$7.9352-Week Range$3.16▼$10.13Volume3.95 million shsAverage Volume5.61 million shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$10.69 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ardelyx alerts: Email Address Ardelyx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.2% Upside$10.69 Price TargetShort InterestBearish11.86% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.58Based on 6 Articles This WeekInsider TradingSelling Shares$4.11 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.34) to ($0.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector88th out of 936 stocksPharmaceutical Preparations Industry31st out of 436 stocks 4.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArdelyx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ardelyx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.86% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Ardelyx has recently decreased by 4.30%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 3.1 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ardelyx this week, compared to 5 articles on an average week.Search Interest37 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat Follows24 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 26% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,109,050.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.34) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 7.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Ardelyx Stock (NASDAQ:ARDX)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesJuly 18, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 7,500 Shares of StockJune 29, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CEO Sells $15,222.90 in StockJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 21, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Earns Outperform Rating from WedbushJuly 20, 2024 | americanbankingnews.comArdelyx's (ARDX) "Buy" Rating Reaffirmed at HC WainwrightJuly 19, 2024 | msn.comArdelyx sues U.S. over Medicare policy proposalJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed Amid Legal Uncertainties and Underlying Value in Ardelyx’s PortfolioJuly 19, 2024 | msn.comArdelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease TreatmentJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 19, 2024 | americanbankingnews.comMichael Raab Sells 7,500 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockJuly 18, 2024 | americanbankingnews.comBrokerages Set Ardelyx, Inc. (NASDAQ:ARDX) Price Target at $11.31July 17, 2024 | reuters.comArdelyx sues US health department over kidney disease drugJuly 17, 2024 | globenewswire.comArdelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful MedicinesJuly 17, 2024 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Sees Large Drop in Short InterestJuly 13, 2024 | seekingalpha.comArdelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain OutlookJuly 2, 2024 | globenewswire.comARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law ViolationsJuly 2, 2024 | globenewswire.comTo Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPAJune 28, 2024 | globenewswire.comArdelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare DisciplinesSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees90Year Founded2007Price Target and Rating Average Stock Price Target$10.69 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+90.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,070,000.00 Net Margins-41.36% Pretax Margin-40.95% Return on Equity-41.65% Return on Assets-23.08% Debt Debt-to-Equity Ratio0.66 Current Ratio4.53 Quick Ratio4.36 Sales & Book Value Annual Sales$124.46 million Price / Sales10.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book7.81Miscellaneous Outstanding Shares232,700,000Free Float219,902,000Market Cap$1.31 billion OptionableOptionable Beta0.83 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 59)President, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 60)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 52)MBA, Chief Financial & Operations Officer and Treasurer Comp: $623.7kMr. Robert FelschSenior VP of Finance & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 60)Chief Legal & Administrative Officer and Secretary Comp: $623.7kMs. Caitlin LowieVice President of Corporate Communications & Investor RelationsMs. Charon Spencer Sr.Chief Human Resources OfficerMr. David P. Rosenbaum (Age 63)Chief Development Officer Comp: $645.4kMr. Robert C. Blanks (Age 64)Chief Regulatory Affairs & Quality Assurance Officer Comp: $590.8kMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPK89bioNASDAQ:ETNBMirum PharmaceuticalsNASDAQ:MIRMFlexion TherapeuticsNASDAQ:FLXNNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 54,843 shares on 7/26/2024Ownership: 0.391%Allspring Global Investments Holdings LLCSold 14,653 shares on 7/26/2024Ownership: 0.028%Calamos Advisors LLCSold 206,775 shares on 7/25/2024Ownership: 0.006%Hennion & Walsh Asset Management Inc.Bought 149,365 shares on 7/20/2024Ownership: 0.253%Nisa Investment Advisors LLCBought 3,233 shares on 7/20/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $6.20 at the start of the year. Since then, ARDX stock has decreased by 9.4% and is now trading at $5.62. View the best growth stocks for 2024 here. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm's quarterly revenue was up 303.5% compared to the same quarter last year. Who are Ardelyx's major shareholders? Ardelyx's top institutional shareholders include Bank of New York Mellon Corp (0.39%), Hennion & Walsh Asset Management Inc. (0.25%), Clay Northam Wealth Management LLC (0.10%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Michael Raab, Susan Rodriguez, Robert Blanks, Laura A Williams, Elizabeth A Grammer, Justin A Renz, David P Rosenbaum, Robert Ora Felsch, Scott D Sandell and Jeffrey W Jacobs. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO) and NVIDIA (NVDA). This page (NASDAQ:ARDX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
